Canada at a glance
- Population
- 41.7 million 2025
- Life expectancy at birth
- 82.1 years, 2024
- People aged 65 and over
- 20.3 % of people, 2025
- Health spending per person
- 6,378 US$ per person, 2024
- Doctors
- 2.82 per 1,000 people, 2023
Updated
Reviewed by Vidhi Upadhyay
Canada In Vivo CAR-T Therapy Market Industry Trends and Forecast to 2034: Segmented by (Delivery, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$354.2 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $6.4 Mn | — | — |
| 2025 (base) | $9.6 Mn | +$3.2 Mn | — |
| 2026 (forecast) | $14.4 Mn | +$4.8 Mn | +49.7% |
| 2027 (forecast) | $21.6 Mn | +$7.2 Mn | +124.1% |
| 2028 (forecast) | $32.3 Mn | +$10.7 Mn | +235.5% |
| 2029 (forecast) | $48.4 Mn | +$16.1 Mn | +402.2% |
| 2030 (forecast) | $72.4 Mn | +$24.1 Mn | +651.8% |
| 2031 (forecast) | $108.5 Mn | +$36.0 Mn | +1,025.5% |
| 2032 (forecast) | $162.4 Mn | +$53.9 Mn | +1,584.8% |
| 2033 (forecast) | $243.0 Mn | +$80.7 Mn | +2,422.2% |
| 2034 (forecast) | $363.8 Mn | +$120.8 Mn | +3,675.7% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $9.6 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $363.8 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 49.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Delivery, indication and end user (see all) |
| Key players | Capstan Therapeutics (AbbVie), Umoja Biopharma, Interius BioTherapeutics, Kelonia Therapeutics, EsoBiotec (AstraZeneca) (see all) |
| Regulator in Canada | Health CanadaSource: Health Canada. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
In vivo CAR-T therapy delivers instructions straight into the body so a patient's own T cells become cancer fighters, without lab manufacturing.
Key segments of the in Vivo CAR-T Therapy market include delivery (Lentiviral Vectors, Lipid Nanoparticles and Targeted Viral Vectors) and indication (Blood Cancers, Autoimmune Diseases and Solid Tumors).
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the in Vivo CAR-T Therapy market.
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the in Vivo CAR-T Therapy market.
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the in Vivo CAR-T Therapy market. Payers are still working out how to pay for one-time cures.
The in Vivo CAR-T Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Health Canada reviews drugs and must authorise them before they can be sold.[1] Each province and territory runs public health insurance under the Canada Health Act, which covers medically necessary hospital and doctor services.[2]
[1] Health Canada. Checked 14 Nov 2026.
[2] Health Canada. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for in Vivo CAR-T Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Canada.
What doctors and scientists are doing in In Vivo CAR-T Therapy right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.
From our blog
Canada · 2 shared keywords
Canada · 1 shared keyword
Canada · 1 shared keyword
Canada · 1 shared keyword
Canada · 1 shared keyword
Canada · 1 shared keyword
Digital Health · Canada
Healthcare Services · Canada
Healthcare Services · Canada
Healthcare Services · Canada
Medical Devices · Canada
Healthcare Services · Canada